Caspian Oliai, MD, MS, University of California, Los Angeles, Los Angeles, CA, discusses the rationale and results of a Phase Ib study evaluating the safety, tolerability, and efficacy of Orca-T, an engineered allogeneic cell therapy, in patients with advanced hematologic malignancies (NCT04013685). This platform, composed of hematopoietic stem cells (HSCs), T regulatory cells (Tregs), and conventional T-cells, aims to reduce the risk of chronic graft-versus-host disease (GvHD) and improve the quality of life (QoL) of transplant recipients whilst preserving the curative potential of allogeneic hematopoietic stem cell transplantation (alloHSCT). The Phase Ib trial showed that patients treated with Orca-T experienced low rates of GvHD and relapse, as well as low rates of graft failure and infections. As a result of these findings, a Phase III study (NCT05316701) was recently launched and is currently open for accrual. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.